Conditions: Uveitis
Keywords: uveitis Cystoid Macular Edema (CME) fluocinolone acetonide non-infectious uveitis affecting the posterior segment
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: no

Brief summary:
The purpose of this study is to collect data on patients with severe uveitis that have required re-implantation of the sustained-release fluocinolone drug delivery device due to depletion of study drug in their previous implanted device.

Detailed description:
Purpose: To collect medical information on a sustained release drug delivery system that delivers the corticosteroid, fluocinolone acetonide, directly into the vitreous cavity of the eye. This system has the potential to maintain therapeutic drug levels in the eye while reducing systemic exposure to the drug to negligible levels. RetisertTM is the trade name for the intravitreal fluocinolone acetonide implant.

Hypothesis: The RetisertTM will be a safe and effective method to manage patients with severe uveitis

Arms:
arm 1: 0.59 mg Fluocinolone Acetonide implant

Interventions: intervention 1: 0.59 mg Fluocinolone Acetonide implant
Intervention descriptions: intervention 1: 0.59 mg Fluocinolone Acetonide implant

Protocol document: